Archives of Neurology · 1960 · 18 citations · 5 references
MedicinePharmacologyPsychiatryNeuropharmacologyNeuropsychiatryPsychopharmacologyPsychotic DisordersSchizophrenia Spectrum DisordersBiomarkers Of PsychosisClimbing PhysiologyIntraperitoneal AdministrationPlasma Protein Biomarkers
Heath et al.1 reported several years ago that a protein substance extracted from the blood of schizophrenic patients would produce transient psychotic symptoms when injected into nonpsychotic persons. Com- parable protein fractions from normal sub- jects were without such effects. Recently, Winter and Flataker2 have stated that in- jections of plasma and serum from psy- chotic patients affect the performance of trained rats in a manner quantitatively, and possibly qualitatively, different from that elicited by samples from nonpsychotic sub- jects. We have used the Winter and Flat-$ aker test 3 to investigate possible differences in plasma protein fractions from psychotic and from nonpsychotic persons when they are injected intraperitoneally into rats. seconds, and this process can be repeated many times throughout the day with no evidence of decrement in performance as measured by the climbing time. Some agents, i.e., lysergic acid diethylamide (LSD-25) and mescaline, which pro¬ duce transient psychotic experiences and confusion in man, will, when injected into the trained rats, increase the climbing time. Usually increases in the climbing time occur within minutes after the intraperitoneal injection of an active substance, reach a maximum effect well within an hour, and diminish to the preinjection level during the fol¬ lowing hours. In our experiments with blood fractions the rats are given four trial climbs prior to injection. Each climbing time is determined to the nearest 0.1 second. The average of these times furnished a performance base line for each animal. After the fourth trial the test substance is injected, and the rats are tested at 15-minute intervals for the next hour. The last test is made 1.5 hours after injection. At this time the major effect of the agent has disappeared, and little would be gained by testing for a longer period. The measure of the effect of the drug is found in the climbing- time delay, which is determined by plotting a performance curve for each animal ; the climbing time, in seconds, is plotted against the time after injection, in minutes. The calculation developed by Winter measures the area under the curve due to the drug effect; i.e., and base-line area is sub¬ tracted from the total area, and the remainder, the climbing-time delay (CTD) is expressed in units, termed minute-seconds.
5
EFFECT ON BEHAVIOR IN HUMANS WITH THE ADMINISTRATION OF TARAXEIN
Robert G. Heath, S Mårtens, Byron E. Leach et al. · American Journal of Psychiatry · 1957 · 90 citations
Medicine, Pharmacology, Psychiatry +12